ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

244
Analysis
Health Care • India
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
•05 Mar 2024 06:44•Broker

Axis Research Scorecard Report for Feb 2024

In Feb’24, the basket inched up further by 1.8%. A few picks that reported excellent returns included SBI (15.5%), Varun Beverage (9.7%), Coal...

Logo
389 Views
Share
•02 Mar 2024 09:56•Broker

Axis Top Picks - Mar 2024

We are extremely happy to share that our Top Picks Basket has delivered an astounding return of 264% since its inception (May’20), which stands...

Logo
490 Views
Share
•22 Feb 2024 22:44•Broker

Pharma Sector: Q3FY24 Review

EBITDA margin witnessed a healthy improvement of 220bps YoY and 55bps QoQ, attributed to normalizing cost inflation and stabilizing prices.

Logo
368 Views
Share
•10 Feb 2024 06:47•Broker

HSIE Results Daily: Lupin, Cummins, Apollo Tyres, Kalpataru Projects International

Lupin: EBITDA growth (+98% YoY and +11% QoQ) was led by 20% YoY sales growth (US: flat QoQ, India +13% YoY, EMEA: +36% YoY and +71% RoW),

Logo
556 Views
Share
bullish•Lupin Ltd
•09 Feb 2024 20:05•Broker

LUPIN Ltd - Margins Guidance Increased

The company’s sales increased by 20.2% YoY to Rs 5,197 Cr, and the growth was majorly led by its US business of $212 (+0.5% Q0Q).

Logo
517 Views
Share
x